Arrow keys move between marks; Enter selects; F opens full screen.

Skip to content
Procura
Get started

Exthera Medical Corporation federal subcontracts

Correct this listing

UEIUEI: the 12-character ID the government gives every company registered for federal work. It replaced the DUNS number in April 2022. Glossary DHBMDQGDJ8S7· CAGECAGE code: a 5-character code that identifies one company location for federal work. A company with several sites can have several. Glossary 5FM86· Martinez, CA· Active registration until Dec 15, 2026

Overview

Primes and buyers on Exthera Medical's subcontracts, US$

Reported subcontract value since award

Click a company to open its profile.

Buyers (office)PrimesThis companyDEF ADVANCEDRESEARCH PROJECTSAGCY (HR0011)$475K · Defense Advance…Battelle Memorial Institute$475K · 1 orderExthera Medical Corporation$475K
Awards toSubcontracts toExthera Medical CorporationConnectedCircle area = dollars

Insight SubcontractorSubcontractor (sub): a company hired by the prime to do part of a federal contract. It works for the prime, not the government. Glossary to Battelle Memorial Institute on 1 order. See more on the Teaming tab

Subcontracts received by fiscal year of report, US$

Hover over a year to see its value.

FY15$475KFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26No subcontracts reported in FY2026 so far

Insight $475K reported in FY2015, its largest year. See more on the Teaming tab

Subcontracts it received

$475K

from 1 prime

Number of subcontracts it received

1

About

From the company's SBA profile, updated Dec 2024

Based in Martinez, California with an office in the Netherlands, ExThera Medical Corporation is a privately held medical device company developing innovative, single-use blood filters capable of capturing a broad range of bacteria, viruses, parasites, toxins and other sepsis mediators. The company’s first product, the Seraph® 100 Microbind® Affinity Blood Filter, is CE Marked and commercially available in Europe. The company is focused is on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, with field deployable versions for biodefense and military use. Bloodstream infections are a global health issue and are increasing in incidence despite significant efforts to find effective treatments. If not identified and treated early, these infections can cause serious illness by progressing to sepsis and septic shock with organ damage or organ failure and death.